Pokrovskaia E E, Osidak L V, Maslennikova I I, Markevich N A, Osipova M V, Drinevskiĭ V P, Ispolatova A V
Vestn Ross Akad Med Nauk. 1995(9):43-5.
Respiratory syncytial (RS) virus is the main cause of severe respiratory infections in newborns and infants during the first year of life. In the recent years, search is under way for chemo- and immune replacement therapy preparations for etiotropic RS-infection therapy. Procedures have been developed to prepare immunoglobulins and Chigain preparations having a target-oriented action. They were clinically tested. There was a positive dynamics in the clinical manifestations of the disease and a positive influence on immunological parameters in children.
呼吸道合胞（RS）病毒是一岁以内新生儿和婴儿严重呼吸道感染的主要病因。近年来，正在寻找用于针对病因治疗RS感染的化学和免疫替代治疗制剂。已经开发出制备具有靶向作用的免疫球蛋白和奇加因制剂的方法。它们已进行了临床试验。疾病的临床表现有积极变化，对儿童的免疫参数有积极影响。
